Bortezomib, Liposome Doxorubicin and Dexamethasone (pdd) is Superior in Safety and Not Inferior in Efficiency to Bortezomib, Doxorubicin and Dexamethasone (pad) As Induction Therapy in New-Diagnosed Multiple Myeloma Patients

Bortezomib, doxorubicin and dexamethasone (PAd) and bortezomib, liposome doxorubicin and dexamethasone (PDd) are widely used as induction chemotherapy regimens in China in the new-diagnosed multiple myeloma patients before autologous stem cell transplantation. There was no data on the comparison in safety and efficiency between those two regimens, so we designed this open-label, randomized, multicenter clinical trial in 10 centers in China （NCT02577783）.